July 17, 2009 / 8:22 PM / 8 years ago

UPDATE 1-Orexigen to unveil obesity trial results on Monday

* Conference call scheduled for Monday

* Shares rise 1.6 percent after hours

LOS ANGELES, July 17 (Reuters) - Orexigen Therapeutics Inc (OREX.O) will release early on Monday results of the three remaining pivotal trials of its experimental obesity drug, Contrave.

    The San Diego-based company said in a statement on Friday that it also will hold a conference call on Monday to discuss the data.

    Orexigen announced in January that its first late-stage trial found that obese patients treated with Contrave lost an average 9.3 percent of their weight, but the results fell short of a bar set by regulators and Wall Street was disappointed.

    Contrave is a pill that combines the antidepressant Wellbutrin, known generically as bupropion, with a sustained- release version of naltrexone, an opioid antagonist used to treat alcoholism and other addictions.

    Shares of Orexigen, which rose 4.4 percent to close at $5.69 on Nasdaq, were up another 1.6 percent at $5.78 after hours. (Reporting by Deena Beasley; editing by Carol Bishopric)

    0 : 0
    • narrow-browser-and-phone
    • medium-browser-and-portrait-tablet
    • landscape-tablet
    • medium-wide-browser
    • wide-browser-and-larger
    • medium-browser-and-landscape-tablet
    • medium-wide-browser-and-larger
    • above-phone
    • portrait-tablet-and-above
    • above-portrait-tablet
    • landscape-tablet-and-above
    • landscape-tablet-and-medium-wide-browser
    • portrait-tablet-and-below
    • landscape-tablet-and-below